Melinta Therapeutics reports positive top-line results from the first of two Phase 3 PROCEED studies (study RX-3341-302, NCT01811732) to evaluate delafloxacin, an investigational fluoroquinolone, compared with vancomycin + aztreonam for the treatment of patients with acute bacterial skin and skin structure infections vaccines.

Mary Szela, Melinta’s president and CEO, said, “These top-line Phase 3 results are consistent with our experience with delafloxacin in Phase 2 clinical trials and are very encouraging, especially in certain patient subgroups whose infections can be challenging to treat.”